- Cancer Types
Information about risk, prevention, screening, symptoms, diagnosis, treatment, and support for all cancers Cancer A to Z - Cancer Treatment
Cancer Treatment
Information about cancer treatment, including surgery, chemotherapy, radiation therapy, clinical trials, proton therapy, complementary medicine, and cutting edge technologies.
- Risk and Prevention
- Cancer Drugs
- Support
Support
Ways for cancer patients and caregivers to cope with cancer, side effects, nutrition, general cancer support issues, grief/end of life issues, and shared survivor's experiences.
- Healthcare Professionals
- Clinical Trials
My Patient Treatment Binder
OncoLink Blogs
What's My Cancer Risk?
OncoPilot: Navigating Your Cancer Journey
Community Events Calendar
OncoLink eNews
Abramson Cancer CenterNCI CANCERLIT® Search: Therapy of Non-Hodgkin's Lymphoma - August 2002
National Cancer Institute®
Last Modified: August 1, 2002
- Zevalin. Novel cancer treatment shrinks tumors.
- [Seven patients with stage I and II primary testicular lymphoma]
- [Therapy-related acute myeloid leukemia following double autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma]
- [Successful treatment with G-CSF and continuous infusion of low-dose cytarabine and etoposide for therapy-related acute myeloid leukemia
- Advances in the management of patients with non-Hodgkin's lymphoma.
- Extranodal lymphoma of MALT-type: perspective at the beginning of the 21st century.
- Role of anti-idiotype vaccines in the modern treatment of human follicular lymphoma.
- Tandem autotransplant as first-line consolidative treatment in poor-risk aggressive lymphoma: a pilot study of 36 patients.
- High dose cyclophosphamide plus recombinant human granulocyte-colony stimulating factor (rhG-CSF) in the treatment of follicular, low grade
- High-dose chemotherapy with hematopoietic stem cell transplantation is effective for nasal and nasal-type CD56+ natural killer cell lymphomas.
- Rituximab: review and clinical applications focusing on non-Hodgkin's lymphoma.
- Photopheresis in cutaneous T-cell lymphoma: five-year experience.
- Narrowband UVB phototherapy for early-stage mycosis fungoides.
- Clinical trials referral resource. Clinical trials and NCI resources for cancer in HIV-positive patients.
- A case of intraductal papillary mucinous tumor of pancreas combined with early gastric cancer and MALToma of stomach.
- AntiCD20 mAbs: modifying therapeutic strategies and outcomes in the treatment of lymphoma patients.
- Helicobacter pylori eradication therapy in primary high-grade gastric MALT lymphoma.
- Rituximab for treatment of intermediate and aggressive B-cell non-Hodgkin's lymphomas.
- High-dose chemotherapy plus allogeneic stem cells to treat chronic lymphocytic leukemia or small lymphocytic lymphoma.
- Results of radiotherapy for orbital and adnexal lymphoma.
- Large bowel lymphoma: an analysis of prognostic factors and therapy in 53 patients.
- Antiretroviral rounds. One patient, with another on the way.
- Extracorporeal photochemotherapy: a case report and update.
- Treatment of cutaneous T cell lymphoma.
- PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.
- Potentiation of vincristine toxicity by itraconazole in children with lymphoid malignancies.
- Assessment of Lymphoma Therapy Using (18)F-FDG PET.
- Phase II study of fludarabine combined with interferon-alpha-2a followed by maintenance therapy with interferon-alpha-2a in patients with
- Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: a 14-year experience at a single institution.
- Alopecia universalis completely resolved following autologous bone marrow transplantation.
- [Non-hodgkin-lymphoma of low malignancy (immunocytoma) and arthritis of the glenohumeral joint]
- CD34+-enriched-CD19+-depleted autologous peripheral blood stem cell transplantation for chronic lymphoproliferative disorders: high purging
- Concurrent spinal cord and vertebral bone marrow radionecrosis 8 years after therapeutic irradiation.
- The role of local radiation therapy for mediastinal disease in adults with T-cell lymphoblastic lymphoma.
Table of Contents
1
UI - 12035643
AU - Anonymous
TI -
Zevalin. Novel cancer treatment shrinks tumors.
SO - Nursing 2002 May;32(5):20
2
UI - 12134704
AU - Kondo T; Wada H; Yata K; Mikami M; Tsujioka T; Suemori S; Suetsugu Y;
TI -
Nakanishi H; Otsuki T; Yamada O; Yawata Y; Morioka M; Tanaka H; Sadahira
Y; Sugihara T
[Seven patients with stage I and II primary testicular lymphoma]
SO - Rinsho Ketsueki 2002 Jun;43(6):473-6
AD - Division of Hematology, Department of Medicine, Kawasaki Medical School.
Seven patients with stage I and II primary testicular lymphoma (PTL)
have been treated since 1990 to the present at Kawasaki Medical School.
All patients, whose median age was 56 yrs, had initially complained of
swelling of the scrotal contents. The lesions were on the right in two
patients, on the left in five, and no patient had bilateral lesions. The
histological diagnosis was diffuse large B-cell type in all patients.
Five patients were classified as Ann Arbor stage I, and two at stage II.
After high-orchiectomy for resection of tumor, two patients received
chemotherapy alone, with a combination of chemotherapy and irradiation
of the contralateral testis in the remaining five. Complete remission
was achieved in all seven patients, but relapse occurred later in one.
As it is recognized that, even in localized stage or low risk group PTL
patients, the relapse rate in the central nervous system (CNS) and
contralateral testis is quite high, chemotherapy, prophylactic CNS
treatment and radiation of the contralateral testis after tumor
resection should be included in the management of PTL.
3
UI - 12134706
AU - Fujii H; Iwai T; Ueda Y; Nakagawa H
TI -
[Therapy-related acute myeloid leukemia following double autologous
peripheral blood stem cell transplantation for non-Hodgkin's lymphoma]
SO - Rinsho Ketsueki 2002 Jun;43(6):482-7
AD - Department of Hematology, Kyoto First Red Cross Hospital.
A 29-year-old male was diagnosed as having non-Hodgkin's lymphoma (NHL,
courses of chemotherapy and double autologous peripheral stem cell
transplantation (total dose: CPA 13,000 mg, BUS 892 mg, L-PAM 150 mg,
MCNU 870 mg, MTX 60 mg, Ara-C 160 mg, DXR 350 mg, VP-16 11,190 mg, VCR 8
mg, CBDCA 700 mg, and MIT 22 mg) for NHL and obtained complete remission
malaise. Laboratory findings showed marked leukocytosis with 85%
leukemia cells, which were positive for alpha-naphthyl butyrate
esterase. Surface-marker analysis of the leukemia cells showed positive
results for CD11b, CD11c, CD13, CD15, CD33, CD56, CD64, CD65, CD71 and
HLA-DR, and chromosomal analysis revealed add(8) (p11), add(9) (p13). He
was diagnosed as having AML (M5a) and was still in complete remission
believed to be from therapy-related leukemia induced by the VP-16 used
for treating NHL, judging by the patient's short clinical course and
monocytic type of leukemia.
4
UI - 12134707
AU - Yamamoto K; Nagata K; Morita Y; Hamaguchi H
TI -
[Successful treatment with G-CSF and continuous infusion of low-dose
cytarabine and etoposide for therapy-related acute myeloid leukemia
developed during chemotherapy for malignant lymphoma]
SO - Rinsho Ketsueki 2002 Jun;43(6):488-92
AD - Department of Hematology, Musashino Red Cross Hospital.
having non-Hodgkin's lymphoma because of right cervical lymphadenopathy.
He had received 8 cycles of chemotherapy including doxorubicin in China.
leukopenia and thrombocytopenia. Peripheral blood showed hemoglobin 12.7
g/dl, platelets 4.1 x 10(4)/microliter and white blood cells
2300/microliter with 15% blasts. Bone marrow was hypocellular with 48%
blasts, which were positive for myeloperoxidase, CD13 and CD33.
Chromosome analysis showed 46,XY, t(9;11) (p21;q23) in all 20 metaphase
spreads. He was diagnosed as having therapy-related acute myeloblastic
leukemia (AML). Because of hypoplastic bone marrow, induction therapy
with the CAG regimen including cytarabine, aclarubicin and
granulocyte-colony stimulating factor (G-CSF) was started, but no
apparent effect was observed. The patient was then treated with the AVG
regimen comprising 250 micrograms of G-CSF and continuous infusion with
20 mg of cytarabine and 50 mg of etoposide for 14 days. Complete
hematological and cytogenetic remission was achieved after two courses
of the AVG regimen. Although it has been shown that the CAG regimen is
effective for refractory and/or secondary AML, our results indicate that
the AVG regimen should be tried for cases of AML resistant to the CAG
regimen.
5
UI - 12113132
AU - Lionberger JM; Armitage JO
TI -
Advances in the management of patients with non-Hodgkin's lymphoma.
SO - Expert Rev Anticancer Ther 2001 Jun;1(1):43-52
AD - University of Nebraska Medical Center, 986545 Nebraska Medical Center,
Omaha, NE 68198-6545, USA.
Non-Hodgkin's lymphoma is the fifth most common cause of death due to
cancer and has been rising at a rate of 4% per year for the last four
decades. Although 'traditional' chemotherapy and radiotherapy have had
important contributions to improving outcomes, new tools in the
treatment of non-Hodgkin's lymphoma are needed. This review describes
therapeutic modalities that are currently being used or are in the
process of being developed and which are based on concepts divergent
from 'traditional' approaches to managing non-Hodgkin's lymphoma.
6
UI - 12113133
AU - Raderer M; Isaacson PG
TI -
Extranodal lymphoma of MALT-type: perspective at the beginning of the
21st century.
SO - Expert Rev Anticancer Ther 2001 Jun;1(1):53-64
AD - Department of Internal Medicine I, Division of Oncology, University of
Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
markus.raderer@akh-wien.ac.at
Extranodal lymphomas arising from mucosa associated lymphoid tissue
(MALT) have become a focus of interest in recent years due to their
unique pathological and clinical properties. The link between
Helicobacter pylori and the development of gastric MALT-type lymphoma
has revolutionized treatment options as up to 80% of patients with early
gastric MALT-type lymphoma achieve complete remission of the tumor
following eradication of H. pylori. As opposed to surgical intervention,
which has been the preferred form of treatment in the past, organ
conserving approaches are increasingly being applied, as both
irradiation and chemotherapy have given excellent results. However,
mature data from prospective, randomized studies taking into account the
concept of MALT lymphoma as a distinct entity are still lacking in order
to define the optimal approach to the management of MALT-type lymphoma.
7
UI - 12113135
AU - Bendandi M
TI -
Role of anti-idiotype vaccines in the modern treatment of human
follicular lymphoma.
SO - Expert Rev Anticancer Ther 2001 Jun;1(1):65-72
AD - Clinica Universitaria, University of Navarra, Department of Hematology,
Avda. Pio XII, 36 31008 Pamplona, Navarra, Spain. mbendandi@unav.es
Cancer vaccines are currently conceived as therapeutic tools, in
contrast to the prophylactic vaccines that have resolved the problem of
a number of infectious diseases. Among the former, anti-idiotype
vaccines for human follicular lymphoma have begun to produce tangible
clinical results. Just 10 years ago it was not even known whether
patients could be immunized against their own tumor antigens and now as
many as two independent Phase III clinical trials based on this finding
are underway. The rapidity of this development encourages the hope that
active immunotherapy may soon become decisive in oncology. For the time
being, many important results have already been achieved: the evidence
of vaccine-induced, tumor-specific humoral/cellular responses and the
first documented molecular remissions following vaccination.
8
UI - 11843254
AU - Haioun C; Mounier N; Quesnel B; Morel P; Rieux C; Beaujean F; Marolleau
TI -
JP; Belhadj K; Simon D; Gaulard PH; Lepage E; Gisselbrecht CH; Reyes F
Tandem autotransplant as first-line consolidative treatment in poor-risk
aggressive lymphoma: a pilot study of 36 patients.
SO - Ann Oncol 2001 Dec;12(12):1749-55
AD - Service d' Hematologie Clinique, Hjpital Henri Mondor, Creteil, France.
corinne.haioun@hmn.ap-hop-paris.fr
PURPOSE: In the previous LNH87-2 study, consolidative high-dose therapy
followed by stem cell transplantation (HDT) improved disease-free
survival, as well as survival for patients (pts) presenting with two or
three factors of the age-adjusted international prognostic index
(Aa-IPI) in first complete remission (CR). In order to improve further
the outcome of such patients, we conducted a pilot study of
consolidative tandem autotranplant. PATIENTS AND METHODS: Thirty-six
patients (pts) under 60 years of age with two or three factors of the
Aa-IPI were enrolled. Their main characteristics were: diffuse large
B-cell lymphoma (83%), Aa-IPI three factors (50%), and marrow involved
(36)%. The procedure consisted of 1) induction with four cycles of ACVBP
(doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone) 2) in
responding pts, peripheral blood stem cell (PBSC) collection after the
fourth cycle of ACVBP (11 pts) or after an additional mobilization
regimen (Cyclophosphamide-VP16) (17 pts) 3) a first HDT (mitoxantrone,
cyclophosphamide, VP16 and carmustine) followed by PBSC infusion 4) a
second HDT (busulfan, carboplatin and melphalan) followed by PBSC
infusion. Among the 29 patients responding to induction, 28 received the
first HDTand 24 the second. RESULTS: The rates of three-year-event free
survival and survival are 47% (95% confidence interval (95% CI: 31%-63%)
and 50% (95% CI: 37%-69%), respectively. Eighteen patients remained free
of evolutive disease and 18 patients have died, 15 from disease
progression and three from treatment-related toxicity after tandem
transplant (two veno-occlusive disease and one cerebral toxoplasmosis).
CONCLUSION: We conclude that tandem transplant did not improve the
results of the LNH87-2 study in which patients received a single
consolidative HDT.
9
UI - 11911406
AU - Lichtman SM; Petroni G; Schilsky RL; Johnson JL; Perri RT; Niedzwiecki
TI -
D; Sklar J; Barcos M; Peterson BA
High dose cyclophosphamide plus recombinant human granulocyte-colony
stimulating factor (rhG-CSF) in the treatment of follicular, low grade
non-Hodgkin's lymphoma: CALGB 9150.
SO - Leuk Lymphoma 2001 Nov-Dec;42(6):1255-64
AD - Don Monti Division of Oncology, North Shore University Hospital, New
York University School of Medicine, Manhasset, USA.
slichtma@suffolk.lib.ny.us
The main objectives of this study were to determine the feasibility of
administering high doses of cyclophosphamide plus recombinant human
granulocyte-colony stimulating factor (rhG-CSF) every 14-21 days to
patients with follicular small cleaved cell lymphoma. For each patient,
the treatment was not considered feasible if fewer than four cycles of
cyclophosphamide chemotherapy could be administered on schedule (i.e. at
least every 29 days) or (1) hospitalization of the patient for longer
than three days was necessary for neutropenic fever (38 degrees C) or
bacteriologically documented infection in > 50% of the cycles, or (2)
grade > or = 2 hemorrhage in association with thrombocytopenia of grade
> or = 3 severity occurred in > 50% of the cycles or (3) non-hematologic
toxicity (excluding nausea/vomiting and alopecia) of grade > or = 3
occurred in > 50% of cycles. The goal was to have a treatment program
feasible in 75% or more of the treated patients. The secondary
objectives were to determine the toxicities, the complete and partial
response rates, and the time to treatment failure (TTF). The trial also
attempted to assess the effectiveness of this treatment program in
eradicating Bcl-2 rearrangements by PCR, and to assess complete
remission duration in relationship to PCR results in patients who
respond to this chemotherapy program. Patients were required to have
histologically documented non-Hodgkin's lymphoma of the subtypes
follicular, predominantly small cleaved cell (IWF-B) or follicular
mixed, (IWF-C). Patients were required to have Stage IV disease
including histologic evidence of bone marrow involvement. Measurable
disease was required and patients were also required to have one of the
following risk factors: > or = 2 extranodal sites, node or nodal group >
or = 5 cm. Submission of fresh bone marrow for molecular genetic studies
for the presence of Bcl-2-Ig fusion DNA was mandatory in previously
untreated patients. Patients had to be between 18 and physiologic age 55
years (carefully selected patients over age 55 years were also
eligible), expected survival > 2 years, performance status 0-1, and have
adequate renal, hepatic and bone marrow function, and a cardiac ejection
fraction > or = 50%. Cyclophosphamide 4.5 g/m2 i.v. was given with mesna
every 14 days with rhG-CSF support. Twenty-nine patients were accrued to
this trial. The median follow-up time is 5.0 years, with a range of
2.5-6.7 years. The overall response rate was 75% (9 CRs 37.5%, 9PRs
37.5%). The median duration of survival is 5.53 years. The 1-year
estimated probability of freedom from treatment failure was 50% and of
survival at 1 year was 92%. No strong association was observed between
TTF and age, symptomatic stage, histology performance status, number of
extranodal sites or baseline Bcl-2 status. At 3 years the survival of
all patients was 78% and failure free survival was 17%. 15 (62%) of the
24 eligible previously untreated patients met the criteria for
feasibility specified in the protocol. The 95% CI for the feasibility
rate is (44 and 82%). Twenty-two of the 24 (92%) previously untreated
patients had specimens submitted for testing for Bcl-2 rearrangements.
Thirteen of the 22 (59%) were found to have rearrangements at baseline.
Post-treatment specimens were submitted for seven of the 13 patients.
Four of the seven converted to Bcl-2 negative following treatment. Eight
of 13 Bcl-2 positive patients (62%) had a clinical response to
treatment. The 95% exact binomial CI for the total response rate in this
subgroup is (28 and 88%). This study demonstrates that repetitive doses
of cyclophosphamide at 4.5 g/m2 every two weeks with rhG-CSF support can
be administered to selected younger patients with advanced follicular
lymphoma with morphologic involvement of the bone marrow with acceptable
non-hematologic toxicity.
10
UI - 11911411
AU - Takenaka K; Shinagawa K; Maeda Y; Makita M; Kozuka T; Ashiba A; Yamamoto
TI -
K; Fujii N; Nawa Y; Hiramatsu Y; Sunami K; Ishimaru F; Yoshimo T; Kiura
K; Harada M
High-dose chemotherapy with hematopoietic stem cell transplantation is
effective for nasal and nasal-type CD56+ natural killer cell lymphomas.
SO - Leuk Lymphoma 2001 Nov-Dec;42(6):1297-303
AD - Second Department of Internal Medicine, Okayama University Medical
School, Japan. ktakenaka@clubaa.com
CD56+ natural killer (NK) cell lymphomas occur frequently in the nasal
and nasopharyngeal regions and carry a poor prognosis. We have studied
seven cases with NK-cell lymphomas. These lymphomas showed the following
immunophenotype: CD56+, CD2+, sCD3- and Epstein-Barr virus-encoded small
RNAs (EBERs)+. Six patients had localized (stage I or II) disease
involving the nasopharyngeal region, while one had stage III disease.
One patient with stage I disease achieved a complete remission (CR)
after treatment with involved-field irradiation, but subsequently
relapsed and died. The remaining six patients received combination
chemotherapy as primary treatment: five patients with localized stage I
or II disease and one patient with advanced stage III disease. Responses
to initial chemotherapy were generally poor. These six patients received
a variety of salvage chemotherapy regimens, but never achieved a CR.
Subsequently, four of six patients showed a highly aggressive clinical
course and died of disseminated disease within 1 year from the
diagnosis. Three of six patients received high-dose chemotherapy
supported by syngeneic, autologous or allogeneic peripheral blood stem
cell transplantation. Two of the three transplant patients achieved a CR
and are now surviving in continuous CR. Our clinical experience suggests
that myeloablative high-dose chemotherapy and bone marrow rescue by
hematopoietic stem cell transplantation may be an effective salvage
treatment modality for refractory NK-cell lymphomas and could be
considered as a part of the initial therapy for these patients.
11
UI - 12113023
AU - King KM; Younes A
TI -
Rituximab: review and clinical applications focusing on non-Hodgkin's
lymphoma.
SO - Expert Rev Anticancer Ther 2001 Aug;1(2):177-86
AD - Division of Pharmacy, University of Texas M.D. Anderson Cancer Center,
1515 Holcombe Blvd, Houston, TX 77030, USA.
Rituximab (Rituxan) was the first monoclonal antibody approved for
cancer therapy and the first single-agent approved for therapy of
lymphoma. When combined with CHOP, rituximab is the only drug that has
been shown to improve survival of a subpopulation of patients with
diffuse large cell lymphoma during the last three decades. It was
approved by the FDA for the treatment of patients with relapsed or
refractory low-grade or follicular, CD20-positive, B-cell non-Hodgkin's
lymphoma in 1997. Rituximab is also being studied in many other B-cell
malignancies alone and in combination with other agents. Furthermore, it
is currently being evaluated in several nonmalignant diseases, such as
autoimmune disorders. This review will focus on the role of rituximab in
patients with non-Hodgkin's lymphoma.
12
UI - 12118838
AU - Crovetti G; Carabelli A; Berti E; Guizzardi M; Fossati S; De Filippo C;
TI -
Bertani E
Photopheresis in cutaneous T-cell lymphoma: five-year experience.
SO - Int J Artif Organs 2000 Jan;23(1):55-62
AD - Photopheresis Department, St. A. Abate Hospital, Gallarate, Italy.
gcrov@tin.it
BACKGROUND: Cutaneous T-cell lymphoma (CTCL) includes several
lymphoproliferative disorders involving mature T-lymphocyte
proliferation initially confined to the cutis. These affections, after
variable periods, may progress to the blood, limph nodes and visceral
organs. Mycosis fungoides (MF) is the most frequent form of CTCL and has
an indolent clinical course. The therapy of CTCL depends on the stage of
the disease and the patient's general conditions. For advanced cases it
includes chemotherapy, retinoids, and interferon-alpha. Since 1987
extracorporeal photochemotherapy (ECP), a novel immunomodulatory
approach based on apheresis and photoirradiation of leukocytes, has been
successfully introduced for the treatment of advanced CTCL. It can
prolong survival of patients with erythrodermic CTCL without significant
side effects. OBJECTIVE: To review our five-year experience with ECP in
ECP, using two different regimens: two procedures on two consecutive
days at four-week intervals for six months, or at two-week intervals for
three months with progressive tapering in the second three-month period
for the more severe forms. Six patients received ECP with IFN-alpha. ECP
was done using the photopheresis UVAR system and UVAR XTS (Therakos,
West Chester, Pa) and always with 8-MOP liquid formulation injected
directly into the buffy coat bag. Lymphocytes in peripheral blood were
immunophenotypically characterized for each patient and every ECP
session. RESULTS: All patients tolerated ECP well, without significant
side effects. Thirty patients are clinically evaluable (at least three
ECP cycles). A favourable clinical response was obtained in 80.9%
(16/21) of MF patients (complete response 33%, partial response 47.6%)
and in 66% (6/9) of patients in the Sezary's syndrome phase (complete
response 33.3%, partial response 33.3%). Five of the six patients given
IFN-alpha as adjunctive therapy had a PR and one a CR. Four patients are
in CR without therapy at follow-ups of 46, 20, 10 and 8 months. There
have been no changes in the peripheral lymphocyte immunophenotype during
the follow-up. In 19/30 patients the CD95 antigen, correlated with
cellular apoptosis, was expressed and was frequently associated with a
good clinical response. CONCLUSIONS: In our experience ECP achieved
favourable clinical responses in 73% of patients, in monotherapy or in
combination with IFN-alpha, without significant side effects.
13
UI - 12140464
AU - Gathers RC; Scherschun L; Malick F; Fivenson DP; Lim HW
TI -
Narrowband UVB phototherapy for early-stage mycosis fungoides.
SO - J Am Acad Dermatol 2002 Aug;47(2):191-7
AD - Department of Dermatology, Henry Ford Health System, Detroit, MI
48202-2689, USA.
BACKGROUND: Narrowband UVB (NB-UVB) phototherapy has been shown to be
effective for the treatment of various dermatoses. OBJECTIVE: We
evaluated the effect of NB-UVB in the treatment of early stage mycosis
fungoides (MF). METHODS: The response of 24 patients (12 stage IA, 12
stage IB) with patch stage MF to thrice weekly NB-UVB was assessed.
Twelve patients had skin phototypes I-III, and 12 had types IV-VI. Seven
patients had hypopigmented MF. Mean follow-up period was 29.0 weeks.
RESULTS: Thirteen patients (54.2%) had a complete response (CR), 7
(29.2%) had partial response (PR), and 4 (16.7%) had no response.
Specimens from a repeat biopsy in 10 patients with CR showed histologic
clearing in 9 of them. Upon discontinuation of treatment, 4 patients
with CR relapsed, with a mean time to relapse of 12.5 weeks. CONCLUSION:
NB-UVB is a viable, comparably safe, and easily administered alternative
in the management of early stage MF.
14
UI - 11866136
AU - Black JB; Feigal EG; Gore-Langton RE
TI -
Clinical trials referral resource. Clinical trials and NCI resources for
cancer in HIV-positive patients.
SO - Oncology (Huntingt) 2002 Feb;16(2):200-2, 205, 207
AD - National Cancer Institute, USA.
15
UI - 12080246
AU - Lee SY; Son HJ; Kim JJ; Paik SW; Rhee JC; Choi KW
TI -
A case of intraductal papillary mucinous tumor of pancreas combined with
early gastric cancer and MALToma of stomach.
SO - J Clin Gastroenterol 2002 Jul;35(1):109-10
16
UI - 12113055
AU - Grillo-Lopez AJ
TI -
AntiCD20 mAbs: modifying therapeutic strategies and outcomes in the
treatment of lymphoma patients.
SO - Expert Rev Anticancer Ther 2002 Jun;2(3):323-9
AD - Neoplastic and Autoimmune Diseases Research Institute, P.O. Box 3797,
Rancho Santa Fe, CA 92067, USA. agrillo1@aol.com
The first monoclonal antibody for the treatment of cancer, rituximab,
was approved 5 years ago and has had a remarkable impact on the
treatment of non-Hodgkin's lymphomas. Additionally, it sparked a renewed
interest in antibodies in general that has revitalized this field of
research. Multiple antibodies for a variety of malignant and
nonmalignant indications are being evaluated. Some are now approved for
anticancer indications (rituximab, ibritumomab, trastuzumab, gemtuzumab,
alemtuzumab) and others are completing the review process at US (FDA)
and European (EMEA) regulatory agencies. The impact of antiCD20
antibodies, particularly rituximab and ibritumomab, is evident in the
way treatment strategies and outcomes have changed for the lymphoma
patient. Other unconjugated antibodies (including Hu1D10, epratuzumab
and alemtuzumab) and conjugated antibodies (including radiolabeled
tositumomab) are under evaluation.
17
UI - 12105882
AU - Fischbach W
TI -
Helicobacter pylori eradication therapy in primary high-grade gastric
MALT lymphoma.
SO - Gastroenterology 2002 Jul;123(1):393
18
UI - 12166456
AU - Anonymous
TI -
Rituximab for treatment of intermediate and aggressive B-cell
non-Hodgkin's lymphomas.
SO - TEC Bull (Online) 2002 Apr 5;19(1):19-21
19
UI - 12166460
AU - Anonymous
TI -
High-dose chemotherapy plus allogeneic stem cells to treat chronic
lymphocytic leukemia or small lymphocytic lymphoma.
SO - TEC Bull (Online) 2002 Apr 5;19(1):5-9
20
UI - 12029566
AU - Liao SL; Kao SC; Hou PK; Chen MS
TI -
Results of radiotherapy for orbital and adnexal lymphoma.
SO - Orbit 2002 Jun;21(2):117-23
AD - Department of Ophthalmology, National Taiwan University Hospital,
Taipei, Taiwan. lang89@ha.mc.ntu.edu.tw
Twenty-five patients presenting with stage I primary orbital and/or
retrospectively reviewed at National Taiwan University Hospital. Staging
workups included physical examination, chest radiography, blood
analysis, whole-body CT scan, CSF examination and bone marrow biopsy.
The histological types, based on the National Cancer Institute working
formulation, were 17 cases of low-grade and 8 of intermediate lymphoma.
Twenty patients received radiotherapy, while five cases refused. All
patients except two received a radiation dose of 40 Gy, the other two
received 30 Gy. The mean follow-up period was 4.7 +/- 1.6 years (2-8
years). Local control of disease was achieved in all 20 patients, but
one patient with low-grade lymphoma developed disseminated disease with
parotid gland, bone marrow and lung involvement 43 months after
radiotherapy. Two out of five patients who refused treatment with
radiotherapy developed systemic involvement 24 months and 18 months
after diagnosis. Dry eye (45%) and cataract formation (35%) were among
the most frequent complications in this study. One patient developed a
recalcitrant trophic corneal ulcer and ultimately required corneal
transplantation. In conclusion, radiotherapy is a safe and effective
local treatment in the management of primary orbital or adnexal
lymphoma.
21
UI - 12173380
AU - Aviles A; Neri N; Huerta-Guzman J
TI -
Large bowel lymphoma: an analysis of prognostic factors and therapy in
53 patients.
SO - J Surg Oncol 2002 Jun;80(2):111-5
AD - Department of Hematology, Oncology Hospital, National Medical Center,
I.M.S.S., Mexico D.F., Mexico. agaviles@avantel.net
BACKGROUND AND OBJECTIVES: We performed a retrospective analysis to
assess the influence of different prognostic factors, including the
International Prognostic Index (IPI), that can predict the outcome in
patients with primary large bowel lymphoma (Stage IE) treated with
combined therapy (surgery followed by chemotherapy). METHODS: All
patients were treated with radical surgery followed by six cycles of
combined chemotherapy: CHOP-Bleo (cyclophosphamide, doxorubicine,
vincristine, prednisone, and bleomycin) or variants (epirubicin instead
of doxorubicin). In all cases, an multivariate analysis was performed to
identify prognostic factors (if any), including IPI, that can influence
outcome. RESULTS: According to the IPI, event-free survival (EFS) and
overall survival were 85% and 87%, respectively, in patients with low
and low-intermediate clinical risk that was not statistically
significant when compared to patients at high and high-intermediate
clinical risk: 69% and 76% (P = 2). Multivariate analysis failed to
demonstrate the influence of multiple prognostic factors that were
analyzed. CONCLUSIONS: Combined therapy appears to be an excellent
therapeutic approach in this group of patients with prolonged EFS and
survival, and without late toxicity. However, no prognostic factors,
including IPI, could be identified to define the best therapy, probably
because the number of patients, even in large series, is limited.
Multicentric studies are necessary to identify prognostic factors to
define therapy and outcome in this rare clinical presentation of
malignant lymphoma.
22
UI - 12170959
AU - Neu N
TI -
Antiretroviral rounds. One patient, with another on the way.
SO - AIDS Clin Care 2000 May;12(5):42-3
23
UI - 11868976
AU - Knobler E; Warmuth I
TI -
Extracorporeal photochemotherapy: a case report and update.
SO - Cutis 2002 Feb;69(2):119-23
AD - Department of Dermatology, Columbia University, New York, New York
10032, USA.
Extracorporeal photochemotherapy (ECP) was developed at Columbia
Presbyterian Medical Center in the early 1980s for the treatment of
cutaneous T-cell lymphoma (CTCL). ECP is now used primarily in the
treatment of that disease at more than 100 centers worldwide. It also
has been shown to be potentially effective in treating several
autoimmune diseases. Most recently, it has been used in reversing
solid-organ transplant rejection and graft-versus-host disease following
bone-marrow transplantation. In this article, we present the case of one
of the first patients treated with ECP and give an update on the current
status of this therapy.
24
UI - 12077466
AU - Stadler R
TI -
Treatment of cutaneous T cell lymphoma.
SO - Skin Pharmacol Appl Skin Physiol 2002 May-Jun;15(3):139-46
AD - Department of Dermatology, Medical Centre Minden, Germany.
Primary cutaneous T cell lymphomas encompass a wide variety of lymphomas
that are characterized by a distinct clinical presentation. Advanced
biological techniques have allowed a more precise classification in
recent years. Stage-adapted therapy is at present the best approach to
treat cutaneous T cell lymphoma. Copyright 2002 S. Karger AG, Basel
25
UI - 12163626
AU - Kostakoglu L; Coleman M; Leonard JP; Kuji I; Zoe H; Goldsmith SJ
TI -
PET predicts prognosis after 1 cycle of chemotherapy in aggressive
lymphoma and Hodgkin's disease.
SO - J Nucl Med 2002 Aug;43(8):1018-27
AD - Division of Nuclear Medicine, Department of Radiology, Weill Medical
College of Cornell University and New York Presbyterian Hospital, New
York, New York 10021, USA. lak2005@mail.med.cornell.edu
Early identification of chemotherapy-refractory lymphoma patients
provides a basis for alternative treatment strategies. Metabolic imaging
with (18)F-FDG PET offers functional tissue characterization that is
useful for assessing response to therapy. Our objective was to determine
the predictive value of (18)F-FDG PET early during chemotherapy (after 1
cycle) and at the completion of chemotherapy for subsequent
progression-free survival (PFS) in patients with aggressive
non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD). METHODS:
(18)F-FDG PET (dual-head coincidence camera with attenuation correction)
was performed before and after 1 cycle of chemotherapy on 30 patients
(17 NHL, 13 HD; mean age, 52.3 +/- 16.0 y). For 23 of the 30 patients,
(18)F-FDG PET data were also obtained after the completion of
chemotherapy. The patients had a median follow-up of 19 mo (range, 18-24
mo). Follow-up of PFS was compared between patients with positive and
negative (18)F-FDG PET results obtained after the first cycle of
chemotherapy and at the completion of chemotherapy. RESULTS: Positive
(18)F-FDG PET results obtained both after the first cycle and at the
completion of therapy were associated with a shorter PFS (median, 5 and
0 mo, respectively) than were negative (18)F-FDG PET results (PFS
medians not reached). A statistically significant difference in PFS
between positive and negative (18)F-FDG PET results was obtained both
after the first cycle and at the completion of chemotherapy (P < or =
0.001). The PFS and (18)F-FDG PET results obtained after the first cycle
correlated better than those obtained after the completion of
chemotherapy (r(2) = 0.45 vs. 0.17). (18)F-FDG PET had more
false-negative results after the last cycle (6/17 cases, or 35%) than
after the first cycle (2/13 cases, or 15%). Thus, (18)F-FDG PET had
greater sensitivity and positive predictive values after the first cycle
(82% vs. 45.5% and 90% vs. 83%, respectively) than after the last cycle.
CONCLUSION: (18)F-FDG PET after 1 cycle of chemotherapy is predictive of
18-mo outcome in patients with aggressive NHL and HD and may earlier
identify patients who would benefit from more intensive treatment
programs.
26
UI - 11697438
AU - Kamaluddin M; McNally P; Breatnach F; O'Marcaigh A; Webb D; O'Dell E;
TI -
Scanlon P; Butler K; O'Meara A
Potentiation of vincristine toxicity by itraconazole in children with
lymphoid malignancies.
SO - Acta Paediatr 2001 Oct;90(10):1204-7
AD - Department of Haematology Oncology, Our Lady's Hospital for Sick
Children, Crumlin, Dublin, Ireland.
Eight consecutive paediatric patients with acute lymphoblastic leukaemia
(ALL) (n = 7) and T-cell non-Hodgkin's lymphoma (NHL) (n = 1) presenting
within a 5-wk interval were started on a standard induction protocol
which included weekly treatment with vincristine for 4 wk. Itraconazole
was commenced as antifungal prophylaxis, 1-21 d after the first
injection of vincristine. Within 2 to 4 wk, enhanced vincristine
neurotoxicity was noted in all patients, abdominal cramps and
constipation occurred most frequently, and one patient developed a bowel
perforation associated with paralytic ileus. Hyponatraemia associated
with SIADH was observed in three patients and four patients developed
seizures. An additional patient with B cell NHL developed seizures 5 d
after an injection of vincristine. Recovery was complete in all patients
and ranged from 2 d to 15 wk. CONCLUSION: The extent and consistency of
adverse effects documented in this study support the recommendation that
concurrent administration of vincristine and itraconazole should be
avoided.
27
UI - 12163627
AU - Lowe VJ; Wiseman GA
TI -
Assessment of Lymphoma Therapy Using (18)F-FDG PET.
SO - J Nucl Med 2002 Aug;43(8):1028-30
AD - PET Imaging, Department of Radiology, Mayo Clinic Rochester, Minnesota
55905, USA. vlowe@mayo.edu
28
UI - 12151972
AU - Lynch JW; Hei DL; Braylan RC; Rimzsa LM; Staab EV; Bewsher CJ;
TI -
Mendenhall NP; Hudson JK
Phase II study of fludarabine combined with interferon-alpha-2a followed
by maintenance therapy with interferon-alpha-2a in patients with
low-grade non-hodgkin's lymphoma.
SO - Am J Clin Oncol 2002 Aug;25(4):391-7
AD - Division of Hematology and Oncology, University of Florida College of
Medicine, Gainesville, Florida 32610, U.S.A.
Randomized trials suggest improved disease-free survival in low-grade
non-Hodgkin's lymphoma (LGNHL) when interferon is combined with
multiagent chemotherapy. This phase II trial was conducted to
investigate the feasibility of combining fludarabine monophosphate
(fludarabine) and IFN in a regimen for treatment of LGNHL. Twenty-one
patients were evaluable. Median age was 55 years, and patients had been
treated with an average of 1.7 chemotherapy regimens before enrollment.
Patients received 25 mg/m2 of fludarabine intravenously on days 1
through 5 followed by 2 x 10(6) U/m2 of interferon-alpha-2a
subcutaneously on days 22 through 26. Cycles were repeated every 4 weeks
with delays and dose modifications for significant cytopenias. Patients
were restaged after cycles 4 and 8, and those with at least a partial
response to therapy were given maintenance therapy consisting of 2 x
10(6) U/m2 interferon-alpha-2a subcutaneously three times per week for 6
months. The overall response rate was 76% with a 25% complete response
(CR) rate. Overall response rates were 75% (3/4 with 2 CR's) for
chemotherapy-naive patients and 76% (13/17 with 3 CR's) for previously
treated patients. Median time to progression was 12 months, and
currently two patients are without evidence of progression at a median
follow-up of 55 months. Grade III or greater toxicities included
neutropenia (39%), anemia (17%), thrombocytopenia (5%), fevers/chills
(5%), and fatigue (5%). Fludarabine and interferon can be effectively
and safely combined in a regimen with significant activity against
LGNHL. A modification of this regimen may be suitable for further study.
29
UI - 12164743
AU - Suchin KR; Cucchiara AJ; Gottleib SL; Wolfe JT; DeNardo BJ; Macey WH;
TI -
Bromley PG; Vittorio CC; Rook AH
Treatment of cutaneous T-cell lymphoma with combined immunomodulatory
therapy: a 14-year experience at a single institution.
SO - Arch Dermatol 2002 Aug;138(8):1054-60
AD - Department of Dermatology and General Clinical Research Center, Hospital
of the University of Pennsylvania, Philadelphia, PA 19104-4283, USA.
OBJECTIVE: To determine the efficacy of multimodality biologic response
therapy for patients with cutaneous T-cell lymphoma (CTCL). DESIGN:
Retrospective cohort study over a 14-year period. SETTING: Tertiary care
university hospital. PATIENTS: A consecutive sample of patients was
studied, all 47 of whom carried the clinical and laboratory diagnosis of
CTCL: 68% of patients had stage III or IV disease, and 89% had
circulating malignant T cells. INTERVENTIONS: All 47 patients received
photopheresis for 6 or more cycles. Thirty-one patients received
treatment with a combination of photopheresis and 1 or more systemic
immunostimulatory agents, including interferon alfa, interferon gamma,
sargramostim, or systemic retinoids for 3 or more months. MAIN OUTCOME
MEASURES: Differences in pretreatment prognostic factors, response
rates, and survival between patients receiving multimodality therapy and
single-modality therapy or historical controls. RESULTS: A total of 79%
of patients responded to therapy: 26% had complete remission, and 53%
had a partial remission. Median survival from initiation of therapy was
74 months. Median survival for patients with stages III and IV and
peripheral blood involvement was 55 months compared with 31 months for
historical controls. Compared with the photopheresis monotherapy group,
the patients receiving combination immunomodulatory therapy had a worse
prognosis at the time of treatment initiation based on multiple
prognostic factors. The positive response rates and median survival
times were 84% and 74 months, respectively, compared with 75% and 66
months, respectively, for the combination immunomodulatory and
photopheresis monotherapy groups (P =.47 for positive response rates and
P =.51 for survival). CONCLUSIONS: Patients with advanced CTCL and
multiple poor prognostic factors who receive treatment with combination
immunomodulatory therapy experience higher clinical response rates and
longer survival than historical controls. Although the group who
received combination therapy had worse prognostic factors at baseline,
they had better response rates and overall survival compared with those
receiving photopheresis monotherapy.
30
UI - 12164760
AU - Feher O; Sant'Ana RO; Valadares AD; Anelli A
TI -
Alopecia universalis completely resolved following autologous bone
marrow transplantation.
SO - Arch Dermatol 2002 Aug;138(8):1102-3
31
UI - 12029594
AU - Braune C; Rittmeister M; Engels K; Kerschbaumer F
TI -
[Non-hodgkin-lymphoma of low malignancy (immunocytoma) and arthritis of
the glenohumeral joint]
SO - Z Orthop Ihre Grenzgeb 2002 Mar-Apr;140(2):199-202
AD - Abteilung fur Rheumaorthopadie der Johann-Wolfgang-Goethe-Universitat
Frankfurt, Germany.
AIM: Oligo- or monarthritis is reported as an uncommon complication of
both acute and chronic leukemia. Childhood leukemias are complicated
more frequently by leukemic arthritis (LA) than adult cases. LA occurs
rather in acute than in chronic leukemia and can present at any stage of
the disease. Proposed pathogenic mechanisms of arthritis in leukemia are
leukemic infiltration of synovial tissue and resulting periosteal and
capsular inflammation. As the primary manifestation of chronic
lymphocytic leukemia (CLL) and immunocytoma (IC), LA is extremely rare.
In such cases osteoarthritis may then be misdiagnosed as the source of
joint disease. METHOD: We report a case of glenohumeral arthritis with
complete rotator cuff tear and humeral head migration in an 88-year-old
patient. Surgery exposed joint effusion, synovitis and chondromalacia
with glenohumeral joint destruction. RESULTS: Histopathological
examination revealed an articular chondrocalcinosis and bone marrow
infiltration by an immunocytoma (B-cell non-Hodgkin lymphoma of low
malignancy). CONCLUSION: Although LA is an uncommon complication in CLL
and IC, it may be considered in elderly patients with lymphocytosis and
arthritis.
32
UI - 12135682
AU - Altes A; Sierra J; Esteve J; Martin-Henao G; Marin P; Sureda A; Briones
TI -
J; Martino R; Villamor N; Colomer D; Carreras E; Garcia J; Brunet S;
Montserrat E
CD34+-enriched-CD19+-depleted autologous peripheral blood stem cell
transplantation for chronic lymphoproliferative disorders: high purging
efficiency but increased risk of severe infections.
SO - Exp Hematol 2002 Jul;30(7):824-30
AD - Clinical Hematology Division, Hospital de la Santa Creu i Sant Pau,
Autonomous University of Barcelona, Barcelona, Spain.
aaltesh@hsp.santpau.es
OBJECTIVE: The main objective of this work was to decrease the incidence
of relapse after autologous stem cell transplantation with a "double
purging" procedure. METHODS: We used a "positive" (CD34) and "negative"
(CD19) double selection method to improve the efficacy of "single
purging" of hematopoietic harvests in poor-prognosis lymphoproliferative
disorders. All patients included in the study had a positive molecular
marker of their disease. Minimal residual disease (MRD) was studied by
flow cytometry and PCR techniques during the purging procedure and after
transplantation. RESULTS: Twenty-six patients fulfilled entry criteria.
Median age of patients was 50 years (range: 33-66); 17 were male and 9
female. Thirteen (50%) of the patients mobilized an adequate number of
CD34+ cells (>or=3 x 10(6)/kg) to proceed with the double-selection
protocol. Twelve of the 13 harvests became PCR negative after purging.
Ten patients were grafted with the selected products and all but one
engrafted without delay. After a median follow-up of 30 months, 2 of 10
patients suffered a molecular relapse at 7 and 19 months respectively.
The earlier relapse was observed in the patient who received a MRD+
product. Only one patient experienced a clinical relapse. Three patients
died due to obliterans bronchiolitis, pneumococcal sepsis, and septic
shock of unknown origin, respectively, and three others presented
life-threatening infections. CONCLUSION: Therefore, CD34+/CD19+
positive/negative selection is an effective purging approach in patients
with chronic lymphoproliferative disorders. This favorable effect is,
however, counterbalanced by the high frequency of life-threatening
infections.
33
UI - 11942381
AU - Warscotte L; Duprez T; Lonneux M; Michaux L; Renard L; Sindic CJ;
TI -
Lecouvet FE
Concurrent spinal cord and vertebral bone marrow radionecrosis 8 years
after therapeutic irradiation.
SO - Neuroradiology 2002 Mar;44(3):245-8
AD - Department of Neurology, Universite catholique de Louvain, Cliniques
universitaires Saint-Luc, Brussels, Belgium.
Concurrent radionecrosis within the spinal cord and the bone marrow at
the same thoracic level was observed 8 years after localized therapeutic
irradiation in a patient who had undergone repeated cycles of
radiotherapy, glucocorticoid treatment, and chemotherapy for a
non-Hodgkin's lymphoma. Mechanisms combining radiotoxic potentialization
by glucocorticoids/alkylating agents and delayed radiation-induced
vasculitis involving the common arterial pathways to the spinal cord and
to the vertebrae were speculated to have acted in a synergistic way.
34
UI - 12173345
AU - Dabaja BS; Ha CS; Thomas DA; Wilder RB; Gopal R; Cortes J; Bueso-Ramos
TI -
C; Hess MA; Cox JD; Kantarjian HM
The role of local radiation therapy for mediastinal disease in adults
with T-cell lymphoblastic lymphoma.
SO - Cancer 2002 May 15;94(10):2738-44
AD - Department of Radiation Oncology, University of Texas M.D. Anderson
Cancer Center, Box 97, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
chulha@mdanderson.org
BACKGROUND: Mediastinal recurrence remains the most common cause of
failure in patients with mediastinal T-cell lymphoblastic lymphoma
(LBL). The role of mediastinal radiation therapy in improving local
disease control and overall prognosis is not well-known with modern
intensive chemotherapy. The objective of this study was to investigate
the role of mediastinal radiation therapy in patients who achieve a
complete response (CR) to chemotherapy. METHODS: The authors reviewed 47
patients with mediastinal T-cell LBL with or without bone marrow (BM)
involvement who presented between 1980 and 1998. The median patient age
was 25 years, and 33 patients (70%) were males. BM involvement was
present in 16 patients (34%), 5 patients (11%) were in leukemic phase,
lymph node involvement in was present 23 patients (49%),
hepatosplenomegaly was present in 4 patients (9%), and pleural effusions
were present in 22 patients (45%). The initial chemotherapy regimens
were fractionated cyclophosphamide, vincristine, doxorubicin, and
dexamethasone (hyper-CVAD) in 23 patients; cyclophosphamide,
vincristine, doxorubicin, and dexamethasone in 9 patients; vincristine,
doxorubicin, and dexamethasone in 4 patients; cyclophosphamide,
doxorubicin, vincristine, and prednisone in 4 patients; and other in 7
patients. Forty-three patients achieved a CR to chemotherapy and were
the subject of this analysis. Nineteen of those patients received
adjuvant mediastinal radiation therapy at a dose ranging from 26 grays
(Gy) to 39 Gy. RESULTS: There was no difference in patient
characteristics between the 19 patients who were treated with
mediastinal radiation therapy and the 24 patients who did not receive
mediastinal radiation therapy. The median follow-up for all 43 patients
was 43 months. The 5-year overall survival (OS) rate was 66%, and the
freedom from progression (FFP) rate was 64%. None of 19 patients who
received radiation therapy experienced a mediastinal recurrence compared
with 8 of 24 patients who did not receive radiation therapy and
experienced a mediastinal recurrence. Patients who were treated with
mediastinal radiation therapy had a significantly better mediastinal FFP
rate (P = 0.01), but the differences in overall FFP and OS rates were
not significant (P = 0.14 and P = 0.25, respectively). The effectiveness
of the hyper-CVAD regimen seemed to underscore the role of mediastinal
radiation therapy; only 2 patients experienced a recurrence among 16
patients who received mediastinal radiation therapy, both outside the
mediastinum. This compared with two patients who experienced a
recurrence among six patients who did not receive mediastinal radiation
therapy, both in the mediastinum. CONCLUSIONS: Local radiation therapy
significantly decreased the risk of mediastinal recurrence in adult
patients with mediastinal T-cell lymphoblastic lymphoma. The benefit of
adjuvant radiation therapy was particularly evident in patients treated
with more intensive chemotherapy regimens.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
